What You Will Learn
- • Why Poly Medicure stock rallied 11% in a single day
- • Q2 FY26 results breakdown: revenue, profit, and margin analysis
- • Italy Citieffe acquisition and European expansion strategy
- • Valuation analysis: P/E ratio, target price, and buy/sell/hold recommendation
Why Poly Medicure Stock Rallied 11%
Poly Medicure delivered strong Q2 FY26 results that exceeded market expectations. The company reported a 5% year-on-year rise in consolidated net profit to Rs 91.8 crore, aided by healthy domestic sales and new product launches. Domestic revenue jumped 17% year-on-year, showing strong traction in the Indian medical devices market.
The rally was triggered by three catalysts: strong Q2 results, completion of the Italy Citieffe acquisition, and ESOP allotment signaling insider confidence. The combined effect created a powerful bullish sentiment that pushed the stock up 11.19% in a single trading session.
Q2 FY26 Financial Results
| Metric | Q2 FY25 | Q2 FY26 | Change |
|---|---|---|---|
| Net Profit | Rs 87.5 Cr | Rs 91.8 Cr | +5% YoY |
| Domestic Revenue | — | — | +17% YoY |
| Revenue Growth | — | — | +16.4% YoY (Q3) |
| FY26 Revenue Guidance | 16% growth (revised from 20%) | — | |
| EBITDA Margin Guidance | 25-27% | Stable | |
The domestic revenue growth of 17% is particularly impressive given the competitive Indian medical devices market. Poly Medicure has been gaining market share through new product launches and expanded distribution. The company expects overall revenue growth of 16% for FY26, revised down from the earlier 20% guidance due to a weak June quarter.
Italy Citieffe Acquisition
Poly Medicure completed the acquisition of Medistream SA (Citieffe Group) for Rs 324 crore (EUR 31 million). Citieffe, based in Italy, specializes in orthopedic implants and has a strong presence in the European and US markets. The acquisition gives Poly Medicure a gateway into the global orthopedics market.
According to Baker McKenzie, the transaction was completed on November 6, 2025. This strategic acquisition provides PolyMed with access to Citieffe's established distribution network and product portfolio in orthopedic implants. The company plans to build a substantial business in the US over the next 4-5 years, as stated by MD Himanshu Baid.
Poly Medicure has made 3 acquisitions in total — 2 in Italy and 1 in Netherlands — primarily focusing on the orthopedics sector. This aggressive acquisition strategy positions the company as a global player in medical devices, not just an Indian manufacturer.
Valuation and Investment Analysis
Poly Medicure currently trades at a P/E ratio of approximately 42-45x, which is below its 10-year median of 54.4x. The current market cap stands at approximately Rs 13,472 crore. The stock has a 52-week range of Rs 2,200 to Rs 3,200, with the current price around Rs 1,350.
Analyst consensus shows an average 1-year price target of Rs 1,731, with a range of Rs 1,371 to Rs 2,050. Simply Wall St projects a price target of Rs 2,300, down from Rs 2,487, implying 20% upside from current levels. The valuation appears attractive given the company's growth trajectory and acquisition pipeline.
✓ Final Verdict
Poly Medicure is a strong long-term play in the Indian medical devices sector. The 17% domestic revenue growth, Italy acquisition, and 16% FY26 revenue guidance provide solid fundamentals. At P/E of 42x, the stock trades below its historical average. For long-term investors with 3-5 year horizon, Poly Medicure offers attractive risk-reward. Track Q3 results for margin recovery confirmation.
Last Updated: May 31, 2026 | Source: CNBCTV18, Mint, Yahoo Finance, Simply Wall St, Baker McKenzie